Bernstein Eden Y, Fu Christina X, Ayanian John Z, Curto Vilsa E, Anderson Timothy S, Landon Bruce E
Division of Hospital Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA.
J Gen Intern Med. 2025 Feb 10. doi: 10.1007/s11606-025-09413-w.
Medicare Advantage (MA) includes incentives to reduce health care spending and insures over half of Medicare eligible adults. Substance use disorders (SUD) are common in this population.
To compare clinical outcomes between MA and traditional Medicare beneficiaries hospitalized with SUD.
Retrospective cohort.
Medicare beneficiaries hospitalized for alcohol withdrawal or opioid overdose from 2016 to 2021.
Primary outcomes included mortality and all-cause readmissions within 30 days of discharge. Secondary outcomes included use of SUD medications.
Of 104,833 beneficiaries hospitalized for alcohol withdrawal (mean age 62.1 [SD 11.5] years, 71.8% male) and 75,463 hospitalized for opioid overdose (mean age 64.5 [SD 12.5] years, 40.8% male), 36.4% and 37.3% were enrolled in MA, respectively. Adjusted rates of 30-day mortality were lower in MA for alcohol withdrawal (unadjusted 2.5% in MA vs 2.4% in traditional Medicare; adjusted difference -0.27 pp [95% CI -0.47, -0.08]) but similar for opioid overdose (7.8% in MA vs 7.9% in traditional Medicare; adjusted difference -0.13 pp [-0.54, 0.27]). Rates of 30-day readmissions were lower in MA for both alcohol withdrawal (12.3% in MA vs 13.7% in traditional Medicare; adjusted difference -1.01 pp [95% CI -1.44, -0.59]) and opioid overdose (14.8% in MA vs 17.6% in traditional Medicare; adjusted difference -1.93 pp [95% CI -2.49, -1.37]). Enrollment in MA was associated with lower use of medications for alcohol use disorder (unadjusted 9.6% in MA vs 11.3% in traditional Medicare; adjusted difference -1.66 pp [95% CI -2.72, -0.60]) but higher use of medications for opioid use disorder (unadjusted 4.9% in MA vs 4.2% in traditional Medicare; adjusted difference, 0.82 pp [95% CI 0.08, 1.57]).
Compared to traditional Medicare, MA was associated with modestly lower 30-day mortality after alcohol withdrawal, lower 30-day readmission rates after alcohol withdrawal and opioid overdose hospitalizations, and mixed findings on medication use.
医疗保险优势计划(MA)包含降低医疗保健支出的激励措施,为超过半数符合医疗保险资格的成年人提供保险。物质使用障碍(SUD)在该人群中很常见。
比较因物质使用障碍住院的MA受益人与传统医疗保险受益人的临床结局。
回顾性队列研究。
2016年至2021年因酒精戒断或阿片类药物过量住院的医疗保险受益人。
主要结局包括出院后30天内的死亡率和全因再入院率。次要结局包括物质使用障碍药物的使用情况。
在104,833名因酒精戒断住院的受益人(平均年龄62.1岁[标准差11.5],71.8%为男性)和75,463名因阿片类药物过量住院的受益人(平均年龄64.5岁[标准差12.5],40.8%为男性)中,分别有36.4%和37.3%参加了MA。MA组酒精戒断患者的30天调整死亡率较低(MA组未调整率为2.5%,传统医疗保险组为2.4%;调整差异为-0.27个百分点[95%置信区间-0.47,-0.08]),但阿片类药物过量患者的情况相似(MA组为7.8%,传统医疗保险组为7.9%;调整差异为-0.13个百分点[-0.54,0.27])。MA组酒精戒断和阿片类药物过量患者的30天再入院率均较低(酒精戒断:MA组为12.3%,传统医疗保险组为13.7%;调整差异为-1.01个百分点[95%置信区间-1.44,-0.59];阿片类药物过量:MA组为14.8%,传统医疗保险组为17.6%;调整差异为-1.93个百分点[95%置信区间-2.49,-1.37])。参加MA与酒精使用障碍药物使用减少相关(MA组未调整率为9.6%,传统医疗保险组为11.3%;调整差异为-1.66个百分点[95%置信区间-2.72,-0.60]),但与阿片类药物使用障碍药物使用增加相关(MA组未调整率为4.9%,传统医疗保险组为4.2%;调整差异为0.82个百分点[95%置信区间0.08,1.57])。
与传统医疗保险相比,MA与酒精戒断后30天死亡率略有降低、酒精戒断和阿片类药物过量住院后30天再入院率降低以及药物使用方面的混合结果相关。